Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
    Meeting Abstract

    Rosenberg, J. E.; Milowsky, M.; Ramamurthy, C.; Mar, N.; McKay, R. R.; Friedlander, T.; Ferrario, C.; Bracarda, S.; George, S.; Moon, H.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial
    Meeting Abstract

    Motzer, R. J.; Russo, P.; Gruenwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O. A.; Buti, S.; Barthelemy, P.; Goh, J. C. H.; Ye, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)
    Meeting Abstract

    Choueiri, T. K.; Powles, T. B.; Albiges, L.; Burotto, M.; Szczylik, C.; Zurawski, B.; Riuz, E. Y.; Maruzzo, M.; Zaizar, A. S.; Fein, L. E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT)
    Meeting Abstract

    Kasper, B.; Ratan, R.; Alcindor, T.; Schoeffski, P.; van Der Graaf, W. T. A.; Wilky, B. A.; Riedel, R. F.; Lim, A.; Smith, L. M.; Moody, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC
    Meeting Abstract

    Strickler, J. H.; Cercek, A.; Siena, S.; Andre, T.; Ng, K.; Van Cutsem, E.; Wu, C.; Paulson, A. S.; Hubbard, J.; Coveler, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600-or NRAS-mutant melanoma
    Meeting Abstract

    Lebbe, C.; Long, G. V.; Robert, C.; Hamid, O.; Atkinson, V. G.; Shoushtari, A. N.; Daud, A.; Bechter, O. E.; Schadendorf, D.; Sullivan, R. J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)
    Meeting Abstract

    Aggarwal, R.; Heller, G.; Hillman, D.; Xiao, H.; Picus, J.; Wang, J.; Taplin, M. E.; Dorff, T.; Appleman, L. J.; Weckstein, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Tabernero, J.; Yoshino, T.; Kim, T. W.; Yaeger, R.; Desai, J.; Wasan, H. S.; Van Cutsem, E.; Ciardiello, F.; Maughan, T.; Eng, C.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)
    Meeting Abstract

    Koshkin, V. S.; Powles, T. B.; Iyer, G.; Loriot, Y.; Drakaki, A.; Martinez, I. D.; De Santis, M.; Retz, M.; Jain, R. K.; Chan, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
    Meeting Abstract

    Hollebecque, A.; Borad, M.; Goyal, L.; Schram, A.; Park, J. O.; Cassier, P. A.; Kamath, S. D.; Meng, D. T. W.; Dotan, E.; Kim, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save